Brainstorm Cell Therapeutics Inc. Stock
Stocks
BCLI
US10501E3009
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
OTC Markets
14:24:08 2026-06-04 EDT
|
5-day change | 1st Jan Change | ||
| 0.8469 USD | +9.99% |
|
-29.42% | +53.15% |
| Market Cap | 13.79M 11.9M 11.21M 10.21M 19.09M 1.3B 19.23M 133M 51.5M 666M 51.8M 50.66M 2.19B | P/E 2026 * |
-1.37x | P/E 2027 * | -1.23x |
|---|---|---|---|---|---|
| Enterprise Value | 13.79M 11.9M 11.21M 10.21M 19.09M 1.3B 19.23M 133M 51.5M 666M 51.8M 50.66M 2.19B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
88.82% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Brainstorm Cell Therapeutics Inc.
| 1 day | +9.99% | ||
| 1 week | -29.42% | ||
| Current month | -20.48% | ||
| 1 month | -5.90% | ||
| 3 months | +6.97% | ||
| 6 months | +19.16% | ||
| Current year | +53.15% |
| 1 week | 0.77 |  | 1.3 |
| 1 month | 0.75 | | 1.49 |
| Current year | 0.46 | | 1.69 |
| 1 year | 0.46 | | 1.69 |
| 3 years | 0.46 | | 24.97 |
| 5 years | 0.46 | | 70.5 |
| 10 years | 0.46 | | 269.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 55 | 2013-07-31 |
Peter Pitts
LAW | General Counsel | 67 | 2026-07-23 |
Alla Patlis
DFI | Director of Finance/CFO | 39 | 2021-08-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Irit Arbel
CHM | Chairman | 66 | 2014-04-24 |
Uri Yablonka
BRD | Director/Board Member | 49 | 2014-06-05 |
| Director/Board Member | 63 | 2018-02-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/24/26 | Free | Chairman | 900,000 | 8.1560% | ||
| 7/24/26 | Free | Chairman | 100,000 | 0.9062% | ||
| 5/25/26 | Other | Director | 150,000 | 1.3593% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.99% | -29.42% | +10.89% | -96.54% | 13.79M | |
| -0.51% | -1.39% | +1.68% | +17.14% | 50.14B | |
| +0.69% | -4.97% | +428.41% | +523.78% | 44.85B | |
| +0.68% | +1.01% | +43.55% | +19.98% | 43.43B | |
| -0.05% | -2.80% | +7.67% | +76.75% | 41.14B | |
| +0.43% | -3.26% | +14.75% | +49.08% | 32.92B | |
| +0.60% | +7.34% | - | - | 17.56B | |
| -0.06% | -3.20% | +23.02% | +123.32% | 16.55B | |
| +0.93% | +0.63% | +16.86% | +29.29% | 14.65B | |
| -0.58% | -2.40% | +78.22% | +41.61% | 13.93B | |
| Average | +1.16% | -0.69% | +69.45% | +87.16% | 27.52B | |
| Weighted average by Cap. | +0.16% | -1.13% | +92.03% | +128.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -13.78M -11.88M -11.2M -10.2M -19.07M -1.3B -19.21M -133M -51.44M -665M -51.73M -50.6M -2.19B | -29.97M -25.86M -24.36M -22.19M -41.48M -2.83B -41.79M -288M -112M -1.45B -113M -110M -4.76B |
| Net Debt | - | - |
Employees
19
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-02 | US$1.250 | +7.07% | 19,576 |
| 26-09-01 | US$1.168 | +9.62% | 3,724 |
| 26-08-31 | US$1.065 | -5.19% | 23,401 |
| 26-08-28 | US$1.123 | -3.39% | 3,634 |
| 26-08-27 | US$1.163 | -3.10% | 22,144 |
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.250
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCLI Stock
Select your edition
All financial news and data tailored to specific country editions
